Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.

Exploring immunotherapy in colorectal cancer

Open access
Weng, Junyong, Li, Shanbao, Zhu, Zhonglin, Liu, Qi, Zhang, Ruoxin, Yang, Yufei, Li, Xinxiang · 2022 · Journal of Hematology & Oncology

Abstract

Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the tumor cells, it is difficult to make breakthroughs in traditional strategies. The immune checkpoint blockades (ICB) therapy has made significant progress in the treatment of advanced malignant tumors, and patients who benefit from this therapy may obtain a long-lasting response. Unfortunately, immunotherapy is only effective in a limited number of patients with microsatellite instability—high (MSI-H), and segment initial responders can subsequently develop acquired resistance. From September 4, 2014, the first anti-PD-1/PD-L1 drug Pembrolizumab was approved by the FDA for the second-line treatment of advanced malignant melanoma. Subsequently, it was approved for mCRC second-line treatment in 2017. Immunotherapy has rapidly developed in the past 7 years. The in-depth research of the ICB treatment indicated that the mechanism of colorectal cancer immune-resistance has become gradually clear, and new predictive biomarkers are constantly emerging. Clinical trials examining the effect of immune checkpoints are actively carried out, in order to produce long-lasting effects for mCRC patients. This review summarizes the treatment strategies for mCRC patients, discusses the mechanism and application of ICB in mCRC treatment, outlines the potential markers of the ICB efficacy, lists the key results of the clinical trials, and collects the recent basic research results, in order to provide a theoretical basis and practical direction for immunotherapy strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-022-01294-4

Cites

224 of 224 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proportion of dMMR/MSI-H in different tumor stages
Fig. 1 Proportion of dMMR/MSI-H in different tumor stagesCC BY · PubMed Central
Fig. 2 Mechanism of therapeutic resistance in ICB treatment. The reasons can be summarized as follows: insufficient tumor antigen presentation, tumor antigen presentation damage, T cell exclusion, and immunosuppressive signaling in the TME. The corresponding clinical trials are also marked in the figure
Fig. 2 Mechanism of therapeutic resistance in ICB treatment. The reasons can be summarized as follows: insufficient tumor antigen presentation, tumor antigen presentation damage, T cell exclusion, and immunosuppressive signaling in the TME. The corresponding clinical trials are also marked in the figureCC BY · PubMed Central
Fig. 3 Consensus molecular classification (CMS) and the coordinate immune response cluster (CIRC) typing of CRC
Fig. 3 Consensus molecular classification (CMS) and the coordinate immune response cluster (CIRC) typing of CRCCC BY · PubMed Central
Fig. 4 Controversial roles of IFN-γ in the TME of CRC. Antitumor: IFN-γ signaling from immune cells and a high IFNG.GS/ISG.RS ratio were associated with increased CD8+ T cells and NK cell activation, and high response to ICB immunotherapy. IFN-γ can prompt CD8+ T cells and NK cells infiltration into TME, promote the MHC-I expression, boost Th1 cells polarization, directly induce tumor cells apoptosis or non-apoptotic death, establish tumor cells dormancy and inhibit tumor cells proliferation by IFN-γ/STAT1 pathway or non-STAT1 signaling; immune evasion: IFN-γ signaling released by tumor cells and a low IFNG.GS/ISG.RS ratio were associated with resistance to ICB treatment. IFN-γ can induce tumor antigen loss, recruit MDSC and TAMs into the TME, induce tumor immunoediting, and facilitate the expression of PD-L1, IDO, and arginase in TME
Fig. 4 Controversial roles of IFN-γ in the TME of CRC. Antitumor: IFN-γ signaling from immune cells and a high IFNG.GS/ISG.RS ratio were associated with increased CD8+ T cells and NK cell activation, and high response to ICB immunotherapy. IFN-γ can prompt CD8+ T cells and NK cells infiltration into TME, promote the MHC-I expression, boost Th1 cells polarization, directly induce tumor cells apoptosis or non-apoptotic death, establish tumor cells dormancy and inhibit tumor cells proliferation by IFN-γ/STAT1 pathway or non-STAT1 signaling; immune evasion: IFN-γ signaling released by tumor cells and a low IFNG.GS/ISG.RS ratio were associated with resistance to ICB treatment. IFN-γ can induce tumor antigen loss, recruit MDSC and TAMs into the TME, induce tumor immunoediting, and facilitate the expression of PD-L1, IDO, and arginase in TMECC BY · PubMed Central
Fig. 5 Timeline of ICB therapy in MSI-H/dMMR CRC
Fig. 5 Timeline of ICB therapy in MSI-H/dMMR CRCCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 224 references

Research works printed but not linked: 1

  1. Kim R, et al. 493P - Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): updated results from KEYNOTE-651 cohorts B and D. Ann Oncol. 2020;suppl_4:S409–61.

Cited by

See all 394

Metadata

Authors
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X.
Affiliations
  • Fudan University Shanghai Cancer Center (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
Li, Xinxiang
Venue
Journal of Hematology & Oncology
Published
2022-07-16
Volume
15
Issue
1
Pages
95-95
ISSN
1756-8722 (ISSN-L)
OpenAlex
W4285587152
Cited by
355
References
224
Citations by year
2026: 62 · 2025: 93 · 2024: 127 · 2023: 61 · 2022: 12
FWCI
8.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82003060, 81772599)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
immunotherapy, metastatic colorectal cancer, immune checkpoint blockade, pembrolizumab, PD-1/PD-L1, microsatellite instability-high, acquired resistance, predictive biomarkers, immune resistance mechanisms, second-line therapy, clinical trials
MeSH terms
Humans, Immunologic Factors, Immunotherapy, Colorectal Neoplasms, Microsatellite Instability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exploring immunotherapy in colorectal cancer. https://app.cochat.ai/papers/10.1186/s13045-022-01294-4
The paper
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022). Exploring immunotherapy in colorectal cancer. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-022-01294-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.